Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $...
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Lilly's cancer therapy Lartruvo fails study, shares dropEli Lilly and Co said on Friday its cancer treatment Lartruvo, approved on an ac...
Read more »
Lilly cancer drug fails key trial, will no longer be prescribedEli Lilly and Co said on Friday that its cancer treatment Lartruvo, which had wo...
Read more »
Stocks making the biggest moves midday: Netflix, Boeing, Tesla, Eli Lilly & moreCheck out the companies making headlines midday Friday.
Read more »
Stocks making the biggest moves premarket: Tesla, CVS Health, Eli Lilly, Netflix & moreSome of the names on the move ahead of the open.
Read more »
Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment
Read more »
Eli Lilly to Buy Loxo Oncology in Deal It Values at About $8 BillionEli Lilly said it is buying Loxo Oncology for $235 a share—a 68% premium from Friday’s closing price—in cash, a deal that expands the biopharmaceutical company’s oncology-treatment portfolio.
Read more »
Eli Lilly to buy Loxo Oncology in $8 billion cancer pushThe pharmaceutical company says it is buying Loxo Oncology for $235 a share in cash, a deal that expands the company’s cancer-treatment portfolio.
Read more »
Eli Lilly to spend about $8B on Loxo OncologyEli Lilly is spending about $8 billion in cash to buy Loxo Oncology, as the drugmaker bulks up on cancer treatments that target certain gene abnormalities. Loxo Oncology could launch a drug next year and targets an abnormality that occurs in several tumor types, including some lung and...
Read more »
Eli Lilly CEO: Loxo acquisition can help us treat cancer globally'This is the future of cancer treatment, we believe.' Eli Lilly CEO David Ricks said that Loxo Oncology has 'harnessed the power of emerging science' and that Lilly's acquisition of Loxo can help treat cancer globally.
Read more »